Theriva Biologics
TOVX
20 hedge funds and large institutions have $328K invested in Theriva Biologics in 2024 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 4 closing their positions.
0.14% more ownership
Funds ownership: 0.18% → 0.32% (+0.14%)
0% more funds holding
Funds holding: 20 → 20 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
76% less capital invested
Capital invested by funds: $1.37M → $328K (-$1.04M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
MSD Partners
New York
|
+$209K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$13.9K |
| 3 |
Renaissance Technologies
New York
|
+$12.3K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
+$3.85K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$175 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAG
SageView Advisory Group
Newport Beach,
California
|
-$1M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$11.6K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$10.8K |
| 4 |
Charles Schwab
San Francisco,
California
|
-$6.36K |
| 5 |
LNC
Lincoln National Corp
Radnor,
Pennsylvania
|
-$5.16K |
TOVX Hedge Fund Activity: Q2 2024 in Review
20 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q2 2024, worth a combined $328K — down 76% from $1.37M a quarter earlier.
Fund positioning in TOVX was balanced in Q2 2024: 4 funds opened new positions, 4 closed out, 3 added to existing stakes and 3 trimmed.
The largest buyer was MSD Partners, opening a new position worth an estimated $209K. The largest seller was SageView Advisory Group, exiting entirely with an estimated $1M sold.
- 20 institutional investors held Theriva Biologics (TOVX) as of Q2 2024, unchanged from Q1 2024.
- Funds reported $328K of Theriva Biologics stock for Q2 2024, down 76% quarter-over-quarter.
- 4 funds opened new Theriva Biologics positions in Q2 2024 and 4 closed out, a net change of 0 holders.
- The largest Theriva Biologics buyer in Q2 2024 was MSD Partners, an estimated $209K added.
- The largest Theriva Biologics seller in Q2 2024 was SageView Advisory Group, an estimated $1M sold.
Based on aggregated 13F filings for Q2 2024.